Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease: Structural Brain Biomarkers

Background:Early Alzheimer’s disease (AD) detection using cerebrospinal fluid (CSF) biomarkers has been recommended as enrichment strategy for trials involving mild cognitive impairment (MCI) patients. Objective:To model a prodromal AD trial for identifying MRI structural biomarkers to improve subj ect selection and to be used as surrogate outcomes of disease progression. Methods:APOE ɛ4 specific CSF Aβ42/P-tau cut-offs were used to identify MCI...